… This review summarizes evidence-based approaches to the systemic and local treatment
of the 3 major breast cancer subtypes: hormone receptor positive/ERBB2 negative (HR+/…

Background Metaplastic breast cancer (MBC) is characterized by various combinations of
adenocarcinoma, mesenchymal, and other epithelial components. It was officially recognized …

From 1966 to 1979, 235 patients with operable breast cancer were treated by tumor excision
and radiotherapy. The actuarial survival at 10 years was 94.8% for stage I and 58% for …

Background Metastatic breast cancer (MBC) treatment has changed substantially over time,
but we do not know whether survival post-metastasis has improved at the population level. …

… treatment regimens in advanced breast cancer and evaluated, through a multiple-treatments
meta-analysis (… to prolong survival in advanced breast cancer patients. Data were analyzed …

… analysis demonstrates the equivalence of neoadjuvant and adjuvant treatments for breast
cancer … with neoadjuvant treatment, especially when primary systemic treatment is not …

… Breast cancer (BC) represents one-fourth of all cancer … BC treatment, an increased number
of women are faced with persistent symptoms that are related to the diagnosis and treatment […

… Cancer Data Base (NCDB) to study treatment and survival trends in men and women
treated for breast cancer at participating hospitals from 1985-1992.3, 4 When treatment was …

… of the country are more likely to receive complete trimodality treatment of IBC, we have
highlighted ongoing disparities in breast cancer care. These findings can be used to help develop …

… was diagnosed within 12 months and metachronous when contralateral breast cancer was
… other breast following an initial breast cancer diagnosis. First breast is defined as the breast …